Literature DB >> 6467189

Oxygen-carrying perfluorochemical emulsion as an adjuvant to radiation therapy in mice.

B A Teicher, C M Rose.   

Abstract

The potential of an oxygen-carrying perfluorochemical emulsion (PFCE) to enhance radiation damage in Lewis lung tumor growing in C57BL/6J X DBA/2J F1 mice was examined. PFCE and 95% O2:5% CO2 (carbogen) breathing caused a significant enhancement of single-fraction radiation damage measured by the growth delay assay. The dose-response effect of PFCE was very broad; doses as small as 0.5 ml/mouse were effective, and doses of 0.3 to 0.4 ml/mouse gave maximal enhancement. The peak dose-modifying factor was 2.8 +/- 0.6 (S.E.). The addition of 0.3 ml of perfluorochemical-free annex solution with carbogen breathing produced a smaller enhancement in tumor growth delay; the dose-modifying factor was 1.5 +/- 0.2. When the perfluorochemical treatment was added to a fractionated course of radiation therapy, a dose-modifying effect of 1.8 +/- 0.3 was obtained. Oxygen-carrying PFCE may provide a nontoxic, clinically useful method of increasing the effectiveness of radiation therapy and of certain chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467189

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Effect of a perfluorochemical emulsion on the development of artificial lung metastases in mice.

Authors:  S Rockwell; C G Irvin; M Nierenburg
Journal:  Clin Exp Metastasis       Date:  1986 Jan-Mar       Impact factor: 5.150

2.  The influence of Fluosol-DA and carbogen breathing on the antitumor effects of cyclophosphamide in vivo.

Authors:  G E Kim; C W Song
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.

Authors:  B A Teicher; T S Herman; J Tanaka; B Dezube; A Pardee; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.

Authors:  B A Teicher; T S Herman; S A Holden; K N Cathcart
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.

Authors:  B A Teicher; S D Bernal; S A Holden; K N Cathcart
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 6.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

7.  Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.

Authors:  B A Teicher; T S Herman; R E Hopkins; K Menon
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.

Authors:  B A Teicher; S A Holden; N P Dupuis; Y Kakeji; M Ikebe; Y Emi; D Goff
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

9.  Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin.

Authors:  B A Teicher; J S Lazo; W W Merrill; A E Filderman; C M Rose
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells.

Authors:  M B Parliament; L I Wiebe; A J Franko
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.